BD03

Phase 1Biologic

SSL VAXiGEN

BD03 is one of 29 biologic programs targeting Kidney Transplant. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney TransplantActive, not recruiting

Kidney TransplantPhase 1

Active, not recruiting

Competition

Competitive Landscape

476 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

Nulojix

Bristol-Myers Squibb

Preclinical

16 2

Simulect

Novartis

Preclinical

15 3

Zinbryta

Roche

Preclinical

6 4

Sensipar

Amgen

Preclinical

1 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

1 6

Cysteine Hydrochloride

Novartis

Preclinical

1 7

Radicava

Shionogi

Preclinical

1 8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

4 9

Jardiance

Boehringer Ingelheim

Preclinical

3 10

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Kidney Transplant1 trial

Evaluate Tolerability and Safety of BD03 for Prevention of CMV and BKV Reactivation in Kidney Transplant Recipient

Unknown status·SSL VAXiGEN·Phase 1·NCT03576014·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BD03. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BD03 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BD03. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SL VAXiGEN company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SSL VAXiGEN

BD03

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Kidney Transplant1 trial

References

Drug Info

Quick Facts

Related News